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Abstract
Therapeutic nucleic acids hold great promise for the treatment of disease but require vectors for 
safe and effective delivery. Synthetic nanoparticle vectors composed of poly(β-amino esters) 
(PBAEs) and nucleic acids have previously demonstrated potential utility for local delivery 
applications. To expand potential utility to include systemic delivery of mRNA, here we develop 
hybrid polymer-lipid nanoformulations for systemic delivery to the lung. Through co-formulation 
of PBAEs with lipid-polyethylene glycol (PEG), mRNA formulations were developed with 
increased serum stability and increased in vitro potency. The formulations were capable of 
functional delivery of mRNA to the lungs following intravenous administration in mice. To our 
knowledge, this is the first description of systemic administration of mRNA for delivery to the 
lungs using a degradable polymer-lipid nanoparticle.
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Nucleic acid therapeutics have great potential to treat disease at the genetic level, especially 
in cases where the aberrant phenotype arises from missing or mutated protein(s).[1,2] 
Recent advances with mRNA, including improvements with in vitro transcription, has 
increased interest in the therapeutic potential of this biomolecule.[3] Unlike DNA, mRNA 
need only reach the cytoplasm to induce protein expression, and furthermore bears no 
apparent risk of insertional mutagenesis[4]. However, like DNA delivery, the application of 
mRNA therapy is limited by the need for safe and effective delivery systems.[5] 
Nanoparticles prepared from cationic polymers have been shown to deliver nucleic acids.[6] 
Polyethyleneimine (PEI) has been broadly investigated as a nucleic acid delivery vehicle, as 
its high density of amine groups facilitates efficient complexation with negatively charged 
nucleic acids and buffers the acidic endosomal environment following nanoparticle 
endocytosis.[7,8] However, PEI is not degradable and there are concerns regarding its 
toxicity, features that could limit its use for clinical applications.[9] Poly(β-amino esters) 
(PBAEs) are degradable polycations with demonstrated potential as delivery systems for 
nucleic acid delivery[10] both for in vitro[11,12] and in vivo[13,14] applications.
Previous studies have suggested that serum stability may limit the efficacy of PBAEs for 
systemic administration.[15] To this end, PBAE terpolymer copolymers containing internal 
alkyl tails were developed.[16] The alkyl amine was incorporated to enable formulation of 
terpolymers with other hydrophobic components in order to increase particle stability in 
physiological conditions. Here, we demonstrate that PBAE terpolymer nanoparticles can be 
formulated with a polyethylene glycol-modified lipid (PEG-lipid) and result in serum 
stabilized nanoparticles and improved efficacy. PBAEs that were found to be serum 
stabilized in vitro upon incorporation of PEG-lipid at 7 mol% were evaluated in vivo and 
shown to be capable of mRNA delivery to the lungs in mice following intravenous 
administration.
The PBAEs selected for synthesis in this study were based on analysis of literature results 
from this class of materials for DNA delivery.[16] We synthesized 7 PBAEs that included 6 
lead terpolymers and 1 lead non-terpolymer (i.e. not including the alkyl amine) from the 
monomers shown in Figure 1a. Synthetic methodology was adapted for synthesis in 
dimethylformamide (DMF) and purification in diethylether in order to reduce the possibility 
of toxicity arising from excess monomer (Scheme S1).[16] Polymer characterization was 
performed via GPC, 1H-NMR, and FTIR (Figures S1-3). Nanoparticles (Figure 1b) were 
prepared by mixing each synthesized polymer with mRNA coding for firefly luciferase 
diluted in acidic (pH 5.2) buffer. Nanoparticles were formulated such that the ratio of amine 
groups in the polymer to phosphate groups in the nucleic acid (N/P) was 57; this is 
consistent with a weight ratio of approximately 50:1, similar to what has been used for 
successful PBAE transfections previously.[17]Stable nanoparticles were formed both with 
and without addition of 7 mol% PEG-lipid (C14-PEG2000), based on an in vitro 
optimization study (Figure S4), and particle formation was confirmed by CryoTEM imaging 
(Figure 1c and Figure S5) and dynamic light scattering (Figure 1d, Table S1).
Co-formulation with PEG-lipid was intended to promote PBAE nanoparticle stability under 
physiological conditions, especially in the presence of serum proteins.[16] Polymers 
formulated without PEG-lipid exhibited a dramatic increase in size during dialysis against 
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phosphate buffered saline (PBS) at pH 7.4, while nanoparticles formulated with 7 mol% 
PEG-lipid remained stable both throughout dialysis (Figure S6) and for at least an additional 
two hours of incubation in PBS at 37°C (Figure 2a), as indicated by turbidity measurements.
[18] Nanoparticles prepared from the non-terpolymer, C32-118, co-formulated with PEG-
lipid were also stable under these conditions, suggestive of some PEG-lipid incorporation 
despite the lack of dodecyl amine in C32-118. When nanoparticle solutions were spiked with 
fetal bovine serum (Figure 2b), only two PEGylated terpolymer formulations resisted 
aggregation: DD90-C12-122 and C32-C12-118. All other terpolymer nanoparticles 
agglomerated and eventually precipitated from solution, as confirmed by RNA quantification 
in the supernatant at the experiment endpoint (Figure S7). The rescue of serum stability for 
representative agglomerating nanoparticles (DD24-C12-122 and DD60-C12-122) was 
possible through addition of higher amounts of PEG-lipid (Figure S8a-b). Turbidity assays 
were carried out at a nanoparticle concentration relevant for in vivo injections (50 ng mRNA 
μL−1), suggesting that PEG-lipid can play a significant role in aggregation resistance in 
serum in vivo, independent of polymer properties.
To determine whether serum stability of PBAE nanoparticles correlated with in vitro 
efficacy, HeLa cells were transfected with PBAE nanoparticles (50 ng mRNA per well), with 
and without PEG-lipid, formulated with luciferase-encoding mRNA (Figure 2c). Cell 
luminescence was then measured as an indicator of transfection efficacy and normalized to 
cell viability as determined by fluorescent assay. Commercially acquired jetPEI, a polymeric 
transfection reagent, was used for comparison and formulated according to the protocol-
recommended N/P ratio as well as N/P of 57. The only terpolymer nanoparticles that resisted 
aggregation in serum stability studies, PEGylated DD90-C12-122 and C32-C12-118, were 
also among the most potent transfection materials. Furthermore, these materials showed a 
significant increase in potency when compared with their non-PEGylated counterparts. 
Cytotoxicity data demonstrated that, at an N/P of 57, cells treated with PEGylated DD90-
C12-122 at a dose of 0 – 70 ng mRNA per well retained >75% viability relative to untreated 
cells, despite the lack of a wash step following transfection, and at higher dose DD90-
C12-122 was significantly less toxic than jetPEI (Figure 2d). Nanoparticles which had 
rapidly precipitated from solution in stability studies (i.e. DF90-C12-122 and DF60-
C12-122) were the least effective, further supporting a correlation between serum stability 
and in vitro efficacy. Though the non-terpolymer control (C32-118) had improved efficacy 
following PEGylation, the improvement in C32-C12-118 potency was far greater after 
inclusion of PEG-lipid, potentially as a result of increased PEG-lipid incorporation in the 
nanoparticle mediated by the C12 group as observed in Eltoukhy et al.[16] Interestingly, 
nanoparticles with rescued serum stability by increased PEG-lipid had a decrease in in vitro 
potency (Figure S8c-d). This is suggestive of a limit above which increasing PEG-lipid 
content is detrimental to effective transfection, perhaps as a result of reduced cellular uptake 
or inefficient RNA unpackaging within endosomes.[19] In sum, the stability and in vitro 
efficacy data suggest that the effect of PEG-lipid inclusion on nanoparticle performance is 
dependent on PBAE chemical structure.
The three terpolymers which had the highest in vitro potencies, PEGylated DD90-C12-122, 
DD24-C12-122, and C32-C12-118, were further considered for in vivo testing. C57BL/6 
mice were injected intravenously with all three PEGylated nanoparticles (7 mol% PEG-
Kaczmarek et al. Page 3





















lipid) and a sample non-PEGylated nanoparticle (DD90-C12-122) at an mRNA dose of 0.5 
mg kg−1 mouse. A positive control of jetPEI was included as well. It is noted that for jetPEI 
N/P = 8 was used (the maximum recommended N/P due to toxicity), whereas all PBAE 
nanoparticles were maintained at N/P = 57. In preliminary studies, nanoparticles prepared 
from DD24-C12-122 led to immediate mortality in most mice, an observation attributed to 
aggregation in circulation resulting in lung occlusions,[20] consistent with the serum-
induced agglomeration demonstrated in Figure 2b. When DD24-C12-122 nanoparticles were 
formulated with a higher mol% PEG-lipid to resist aggregation (Figure S8a) no mortality 
was observed, but these nanoparticles also showed no efficacy (Figure S9), corroborating in 
vitro findings (Figure S8c). For mRNA delivered with PEGylated DD90-C12-122 and C32-
C12-118, protein is expressed primarily in the lungs (Figure 3a-b). The impact on in vivo 
efficacy from improved serum stability imparted by PEG-lipid is most clearly seen in 
elevated luminescence following delivery of PEGylated C32-C12-118 compared to non-
PEGylated DD90-C12-122, in spite of their similar potency in vitro. Additionally, the 
luminescence achieved using PEGylated DD90-C12-122 and C32-C12-118 is comparable to 
that obtained via in vivo jetPEI (Figure 3b), and PEGylated DD90-C12-122 mRNA delivery 
is dose dependent (Figure 3c). This stands in stark contrast to previous studies on 
intravenous delivery of PBAE-DNA complexes, in which jetPEI outperformed PBAEs by 
two orders of magnitude in the lungs.[15] A recent study demonstrated in vivo mRNA 
expression in the lungs following pulmonary administration of cationic polymeric 
nanoparticles [21], however, to our knowledge, ours is the first example of biodegradable 
polymeric nanoparticles to successfully delivering mRNA to the lungs following intravenous 
injection in mice.
As PBAE nanoparticles were primarily effective in promoting mRNA translation in the 
lungs, we next studied biodistribution of these delivered mRNA. PEGylated DD90-C12-122 
nanoparticles were formulated with fluorescently-labeled mRNA and injected intravenously 
in mice (0.5 mg kg-1 mRNA). As seen in Figure 3d, fluorescence is detected broadly in all 
organs excised at a similar level at 6 hours post-injection (Figure S10), despite the fact that 
mRNA is primarily expressed in the lungs. Interestingly, many lipid-mRNA nanoparticles in 
the literature also distribute throughout the organs, but deliver mRNA most effectively to the 
liver following systemic administration.[22,23] The disconnect between RNA 
biodistribution and the site of RNA efficacy has also been observed using lipopolymeric 
nanoparticles for siRNA delivery to the lungs[24]. Specific expression in the lungs could be 
related to selective tagging/trafficking by endogenous proteins: For some lipid-RNA 
nanoparticle formulations, liver specificity is due to adsorption of Apolipoprotein E (ApoE) 
onto the nanoparticles, which thereby traffics the formulation to hepatocytes which express 
the ApoE receptor[25]. While the mechanism by which formulations developed here result 
in preferential expression of mRNA in the lung remains unclear, it is possible that, like lipid 
nanoparticles, interaction with serum proteins or surface receptors on lung endothelium may 
account for the lung specificity of our particles. Regardless, the safe and effective delivery of 
nucleic acid to the lungs may have utility in the treatment of a variety of diseases at the 
genetic level, including pulmonary hypertension[26] and cancer.[27]
In conclusion, we have developed PBAE-lipid mRNA nanoparticles with improved serum 
stability, which are capable of delivering mRNA to the lung. To our knowledge, this is the 
Kaczmarek et al. Page 4





















first demonstration of systemic mRNA delivery to the lung using degradable polymeric 
nanoparticles. We hypothesize that degradability of the materials used in the delivery of 
RNA therapeutics may be particularly important for applications requiring repeat dosing of 
mRNA such as protein replacement therapies.[10] The function of PEGylated DD90-
C12-122 and C32-C12-118 nanoparticles demonstrated here warrants continued 
development and optimization to further improve potency. One approach to potentially 
access even more potent formulations would utilize Design of Experiment methodology to 
vary the formulation components, which has been shown to lead to improved mRNA 
delivery efficacy in a separate liver-targeting system.[21] Importantly, these data 
demonstrate a correlation between serum stability and in vivo efficacy: the terpolymers that 
form serum-stable nanoparticles when formulated with a low amount (7 mol%) of PEG-lipid 
also led to the most potent in vivo mRNA delivery. The efficacy of these top-performing 
PEGylated PBAE candidates also compared favorably in vivo to commercially-available 
jetPEI. However, given the low in vivo potency of highly PEGylated serum-stable 
nanoparticles, serum stability alone is not a predictor of in vivo function. Still, in vitro 
assessment of serum stability, when used as a secondary metric following an efficacy screen, 
may prove useful in accelerating the discovery of PBAE formulations for intravenous 
nucleic acid delivery.
Experimental Section
Polymers were synthesized by dissolving diacrylate, amine, and alkyl amine monomers 
(concentration 1M) in anhydrous dimethyl formamide at a molar ratio of 1.2:0.7:0.3 and 
reacted for 48 hours at 90°C. End capping monomers were then added at room temperature 
and reacted for an additional 24 hours, followed by 2 washes with diethyl ether. Polymers 
were re-dissolved in anhydrous dimethyl sulfoxide and stored at −80°C. Nanoparticles were 
synthesized by dissolving mRNA in sodium acetate buffer (pH 5.2) and polymer/PEG-lipid 
(when applicable) in either sodium acetate buffer (for non-PEGylated nanoparticles) or 
ethanol (for PEGylated nanoparticles) as a separate phase. The two phases were mixed 
vigorously in order to form the nanocomplexes. PEGylated particles were subjected to 
dialysis in PBS in order to remove ethanol before experiments.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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PBAE polymer synthesis and nanoparticle formation. (a) Monomers from top-performing 
materials identified previously were chosen. Briefly, step-growth polymerization was 
performed via Michael addition of diacrylates and amines, with dodecyl amine added in the 
case of terpolymers to form a random copolymer. Chains were subsequently reacted with an 
end-capping amine. For nomenclature, “DD90-C12-122” refers to a terpolymer synthesized 
from the DD diacrylate reacted with amine 90 along with the C12 alkylamine, and then end-
capped with amine 122 (see Representative Synthesis section in the Supplementary 
Information). Nanoparticles were then formulated by incorporation of PEG-lipid via 
hydrophobic interactions. (b) Cartoon depiction of PEGylated, mRNA-loaded terpolymer 
nanoparticles. (c) Representative cryoTEM image of DD90-C12-122 formulated with PEG-
lipid. (d) Representative sizing data from dynamic light scattering of DD90-C12-122 
formulated with PEG-lipid.
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PBAE serum stability and in vitro efficacy. (a) PEGylated PBAE nanoparticles were stable 
for approximately 2 hours in PBS at 37°C, as indicated by turbidity measurements. These 
particles were previously dialyzed in PBS for 2 hours at 4°C, a process which results in non-
PEGylated particles aggregating (mean ± SD, n = 3). (b) PEGylated DD90-C12-122 and 
C32-C12-118, as well as PEGylated C32-118 remained stable following addition of 10% v/v 
fetal bovine serum, while others aggregated (mean ± SD, n = 3). (c) PBAE terpolymer 
nanoparticles formulated with luciferase-encoding mRNA promote luciferase protein 
expression in HeLa cells (50 ng/well mRNA dose), as quantified by cellular luminescence. 
Luminescence was normalized to live cell signal using a fluorescent live/dead cell assay. In 
this case, transfection is compared to a commercial polymeric transfection reagent jetPEI. 
(d) Relative viability of cells treated with PEGylated DD90-C12-122 and jetPEI (N/P=57) 
**indicates p<0.01, *** indicates p < 0.001 (mean ± SD, n = 4).
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In vivo efficacy of PBAE nanoparticles. DD90-C12-122. DD90-C12-122 (formulated with 
and without 7 mol% PEG-lipid), PEGylated C32-C12-118, and in vivo jetPEI nanoparticles 
were formulated with luciferase-coding mRNA and delivered via tail vein injection to mice 
at a dose of 0.5 mg mRNA/kg mouse. (a) Representative luminescent image of excised 
organs following PEGylated DD90-C12-122 delivery demonstrate protein expression mainly 
in the lungs. (b) At a dose of 0.5 mg mRNA kg−1 mouse injected intravenously, PEGylated 
DD90-C12-122, as well as PEGylated C32-C12-118, yielded significantly greater 
luminescence than a non-PEGylated counterpart and had protein expression comparable to 
that of jetPEI in the lungs; * indicates p < 0.05, ** indicates p < 0.01. (c) Luminescent 
radiance is dependent on the dose of PEGylated DD90-C12-122 nanoparticles. (d) Imaging 
of mouse organs following injection of PEGylated DD90-C12-122 nanoparticles loaded with 
fluorescent mRNA revealed that nanoparticle biodistribution is similar across major organs 
(representative fluorescent image shown).
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